Although TMB of 10 m/MB would qualify her for pembrolizumab per the tumor agnostic approval, it was deemed not to be ideal in her case given that the Keynote-158 trial that got this approval did not include patients with LMS.6 The BRCA2 mutation provided an option for a PARP inhibitor (PARPi). This evidence concerns the gene BRCA2 and neoplasm.